Singapore markets closed

NVO Jul 2024 180.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.01000.0000 (0.00%)
As of 10:07AM EDT. Market open.
Full screen
Loading interactive chart…
  • Insider Monkey

    Novo Nordisk A/S (NVO): The Most Profitable Stock of the Last 20 Years According to Analysts?

    We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable stocks. The stock market has a long history of generating wealth for investors. While past performance doesn’t guarantee […]

  • Benzinga

    Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval

    On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition. Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic O

  • Zacks

    Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

    Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.